Literature DB >> 31210419

Molecular biomarker-guided anti-angiogenic targeted therapy for malignant glioma.

Chengrui Yan1,2, Jiaru Wang2, Yuyan Yang2, Wenbin Ma2, Xiaolin Chen3.   

Abstract

Despite aggressive multimodality treatment, the prognosis of glioma, especially malignant glioma, remains very poor. After decades of effort, anti-angiogenic therapy has become an important method of cancer treatment in addition to surgery, radiotherapy and chemotherapy. Although the performance of anti-angiogenic therapy in colorectal cancer is good, its performance in malignant glioma remains unsatisfactory. Several phase III clinical trials showed no overall survival benefits. To solve this problem, the division of patients into groups based on their molecular biomarkers is an important step. This paper provides current insights into anti-angiogenic drugs undergoing clinical trials and discusses the potential of molecular biomarkers to guide glioma diagnosis.
© 2019 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.

Entities:  

Keywords:  anti-angiogenic; biomarkers; glioma; molecular; therapy

Mesh：

Substances：

Year:  2019        PMID： 31210419      PMCID： PMC6653115          DOI： 10.1111/jcmm.14417

Source DB:  PubMed          Journal:  J Cell Mol Med        ISSN： 1582-1838            Impact factor:   5.310


  44 in total

Review 1.  Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.

Authors:  Rajeshwar P Verma; Corwin Hansch
Journal:  Bioorg Med Chem       Date:  2007-01-17       Impact factor: 3.641

2.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

Authors:  Quinn T Ostrom; Haley Gittleman; Peter Liao; Chaturia Rouse; Yanwen Chen; Jacqueline Dowling; Yingli Wolinsky; Carol Kruchko; Jill Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

3.  Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.

Authors:  Thomas Sandmann; Richard Bourgon; Josep Garcia; Congfen Li; Timothy Cloughesy; Olivier L Chinot; Wolfgang Wick; Ryo Nishikawa; Warren Mason; Roger Henriksson; Frank Saran; Albert Lai; Nicola Moore; Samir Kharbanda; Franklin Peale; Priti Hegde; Lauren E Abrey; Heidi S Phillips; Carlos Bais
Journal:  J Clin Oncol       Date:  2015-06-29       Impact factor: 44.544

4.  A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas.

Authors:  Teri N Kreisl; Svetlana Kotliarova; John A Butman; Paul S Albert; Lyndon Kim; Luna Musib; Donald Thornton; Howard A Fine
Journal:  Neuro Oncol       Date:  2010-01-22       Impact factor: 12.300

Review 5.  Molecular biomarker-guided anti-angiogenic targeted therapy for malignant glioma.

Authors:  Chengrui Yan; Jiaru Wang; Yuyan Yang; Wenbin Ma; Xiaolin Chen
Journal:  J Cell Mol Med       Date:  2019-06-18       Impact factor: 5.310

6.  Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma.

Authors:  Emeline Tabouret; Françoise Boudouresque; Maryline Barrie; Mona Matta; Celine Boucard; Anderson Loundou; Antoine Carpentier; Marc Sanson; Philippe Metellus; Dominique Figarella-Branger; L'houcine Ouafik; Olivier Chinot
Journal:  Neuro Oncol       Date:  2013-12-09       Impact factor: 12.300

7.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

8.  The role of vascular proliferation in the growth of brain tumors.

Authors:  S Brem
Journal:  Clin Neurosurg       Date:  1976

Review 9.  Angiogenesis: an organizing principle for drug discovery?

Authors:  Judah Folkman
Journal:  Nat Rev Drug Discov       Date:  2007-04       Impact factor: 84.694

10.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors:  Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544
View more
  5 in total

Review 1.  Molecular biomarker-guided anti-angiogenic targeted therapy for malignant glioma.

Authors:  Chengrui Yan; Jiaru Wang; Yuyan Yang; Wenbin Ma; Xiaolin Chen
Journal:  J Cell Mol Med       Date:  2019-06-18       Impact factor: 5.310

2.  Efficacy and safety of bevacizumab combined with temozolomide in the treatment of recurrent malignant gliomas and its influence on serum tumor markers.

Authors:  Jun Lei; Zhi Zhou
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

3.  Clinical significance of long noncoding RNA MNX1-AS1 in human cancers: a meta-analysis of cohort studies and bioinformatics analysis based on TCGA datasets.

Authors:  Kang Chen; Jian-Xin Gan; Ze-Ping Huang; Jun Liu; Hai-Peng Liu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

4.  Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study.

Authors:  Carine Jiguet-Jiglaire; Sebastien Boissonneau; Emilie Denicolai; Victoria Hein; Romain Lasseur; Josep Garcia; Sylvie Romain; Romain Appay; Thomas Graillon; Warren Mason; Antoine F Carpentier; Alba A Brandes; L 'Houcine Ouafik; Wolfgang Wick; Ania Baaziz; Julien P Gigan; Rafael J Argüello; Dominique Figarella-Branger; Olivier Chinot; Emeline Tabouret
Journal:  Acta Neuropathol Commun       Date:  2022-01-03       Impact factor: 7.801

5.  Clinicopathological and Prognostic Significance of ABCC3 in Human Glioma.

Authors:  Dan-Dong Fang; Wei Huang; Gang Cheng; Xiao-Nan Liu; Shi-Min Liu; Bao-Sen Hou; Jian Mao; Hu Zhou
Journal:  J Oncol       Date:  2021-12-23       Impact factor: 4.375
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.